Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength?

Core Viewpoint - Novavax (NVAX) shares experienced a significant increase of 10.9% in the last trading session, closing at $10.82, driven by heightened investor interest in vaccines targeting the H5N1 virus following the first human death from bird flu reported in the U.S. [1][2] Company Summary - Novavax is currently developing a vaccine for the H5N1 virus, which has garnered attention after a recent human fatality linked to bird flu in the U.S. [2] - The company is expected to report a quarterly loss of$0.67 per share, reflecting a year-over-year increase of 53.5%, while revenues are projected to be $90.72 million, down 68.9$0.71 for its upcoming report, representing a year-over-year change of 45.8%, and it also holds a Zacks Rank of 3 (Hold) [5].